Replimune shares collapsed on Tuesday after the U.S. Food and Drug Administration rejected the clinical-stage biotechnology company's proposed advanced melanoma treatment. Shares of the Woburn, Mass., ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Jim Cramer, a stalwart of stock market commentary, recently shifted gears on Bristol-Myers Squibb, pegging his hopes on their ...

The Cancer Immunotherapy market, valued at USD 220.94 billion in 2024, is expected to register robust revenue CAGR of 13.6%.

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

US FDA accepts Bristol Myers Squibb’s sNDA for Sotyktu to treat adults with active psoriatic arthritis: Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] Bristol Mye ...

Bristol-Myers Squibb’s shares (currently trading at $46.80) have posted a disappointing 18% loss, well below the S&P 500’s ...

Our warm weather season is short, and it's important to enjoy the outdoors. The point isn't to be sun-scared — just stay ...